4645-11-8

Usage

Uses

Used in Chemical Synthesis:
2-Bromo-6-ethoxy pyridine is used as a key intermediate in the synthesis of various organic compounds, particularly in the pharmaceutical industry. Its unique structure allows for the formation of new chemical bonds and reactions, making it a valuable component in the creation of novel drug molecules.
Used in Laboratory Research:
2-BROMO-6-ETHOXY PYRIDINE is employed as a research tool in academic and industrial laboratories, where it is utilized to study the properties and reactivity of heterocyclic aromatic compounds. It aids in understanding the fundamental principles of chemical reactions and can contribute to the development of new synthetic methodologies.
Used in Drug Development:
2-Bromo-6-ethoxy pyridine is used as a building block in the development of new pharmaceutical drugs. Its presence in the molecular structure can impart specific biological activities, such as antimicrobial, antiviral, or anticancer properties, depending on the final drug molecule's design.
Used in Material Science:
In the field of material science, 2-bromo-6-ethoxy pyridine can be used to develop new materials with unique properties, such as improved conductivity, stability, or reactivity. Its incorporation into polymers or other materials can lead to the creation of advanced materials for various applications, including electronics, energy storage, and environmental protection.
Always handle 2-bromo-6-ethoxy pyridine with care, as its potential health effects and danger levels under certain conditions are not broadly studied yet. Proper safety measures, such as wearing protective gear and working in a controlled environment, should be taken to minimize any risks associated with its use.

InChI:InChI=1/C7H8BrNO/c1-2-10-7-5-3-4-6(8)9-7/h3-5H,2H2,1H3

Upstream product

• 626-05-1 2,6-Dibromopyridine 
• 27992-32-1 6-bromo-2-pyridone 
• 75-03-6 ethyl iodide 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 

Downstream Products

• 59880-62-5 α-phenyl-α-(6-ethoxy-2-pyridyl)methanol 
• 1082827-09-5 N-[(2-chloro-4-fluorophenyl)methyl]-2-{1-[6-(ethyloxy)-2-pyridinyl]-1H-pyrazol-4-yl}acetamide 
• 2402-79-1 2,3,5,6-tetrachloropyridine 
• 6515-38-4 3,5,6-trichloropyridin-2 ol 
• 2402-78-0 2,6-dichloropyridine 
• 3346-63-2 2,6-diamino-3-nitro-pyridine 
• 5140-72-7 2-bromo-6-chloro-pyridine 
• 857992-18-8 6-ethoxy-2-bromo-3-nitro-pyridine 
• 16879-02-0 6-chloro-2-hydroxypyridine 
• 13472-57-6 2,6-bis(ethoxy)pyridine 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR

The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee 1, and includes an application of the compound in treating various types of tumors.

Novel synthesis method for ortho-alkane superseded pyridine

The invention relates to a novel synthesis method for ortho-alkane superseded pyridine. According to the method, ortho halogenated pyridine serves as raw materials, the ortho halogenated pyridine and corresponding alcohol react to obtain the ortho-alkane superseded pyridine under the action of sodium hydroxide. The reaction has universality for the ortho halogenated pyridine, and the method is simple and practical. Influence of consumption of the sodium hydroxide on mono-substitution and di-substitution in the reaction is inspected, alkoxy mono-substitution products and alkoxy di-substitution production are acquired, and a novel simply-operated, economical and favorable process for synthesis ortho-alkane superseded pyridine is provided.

Heterocyclic compounds as inhibitors of factor VIIa

The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Metalloprotease inhibitors

Compounds of formula (I) and pharmaceutically-acceptable derivatives thereof, are matrix metalloprotease inhibitors, useful in treatment of conditions mediated by matrix metalloproteases, such as chronic dermal ulcers.

Composition for the treatment of damaged tissue

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

Selective N-functionalization of 6-substituted-2-pyridones

6-Substituted-2-pyridones can be selectively N-alkylated by treatment with NaH/LiBr in a mixture of DMF and DME. Yields of N-propargylated, N-allylated, and other N-functionalized products are good, and only small amounts of the isomeric O-alkylated produ